ICU Medical (ICUI) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed ICU Medical (ICUI) over the past year, gaining 147.1% versus a gain of 32.1%. Over five years, PLSE leads with a +126.7% price change compared with -32.4% for ICUI. ICU Medical is the larger company by market cap ($3.93 billion vs $3.56 billion), about 1.1 times the size.
ICU Medical converts more of its revenue into profit, with a net margin of 0.0% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICUI | PLSE |
|---|---|---|
| Share price | $157.18 | $49.98 |
| Market cap | $3.93B | $3.56B |
| 1-day change | +0.74% | +1.81% |
| YTD return | +9.36% | +257.54% |
| 1-year return | +32.12% | +147.06% |
| 5-year return | -32.41% | +126.74% |
| P/E ratio (TTM) | 132.08 | — |
| Forward P/E | 16.29 | — |
| EPS (TTM) | $1.19 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.23B | $350.00K |
| Revenue growth (YoY) | -6.33% | — |
| Net income (latest FY) | $732.00K | $-72.78M |
| Gross margin | 36.84% | -54.00% |
| Operating margin | 1.92% | -21982.57% |
| Net margin | 0.03% | -20794.57% |
| 52-week high | $192.85 | $58.90 |
| 52-week low | $112.50 | $12.56 |
| Distance from 52-week high | -18.50% | -15.14% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +23.03% | +13.05% |
| Average volume | 277.57K | 506.50K |
| Shares outstanding | 25.01M | 71.32M |
| Employees | 13,000 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLSE has outperformed ICUI by 114.9 percentage points over the past year.
- ICU Medical is more profitable, keeping 0.0 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About ICU Medical
ICUI stock →ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products.
Health Care · Medical/Dental Instruments · 13,000 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
ICUI vs PLSE FAQ
Which is bigger, ICU Medical or Pulse Biosciences?
ICU Medical (ICUI) is larger, with a market capitalization of $3.93B compared with $3.56B for Pulse Biosciences (PLSE).
Which stock has performed better over the past year, ICUI or PLSE?
PLSE returned +147.06% over the past 12 months, compared with +32.12% for ICUI (price return, excluding dividends). Past performance does not predict future results.
Are ICU Medical and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.